Johnson & Johnson Research and Development Expense
Johnson & Johnson (JNJ) reported Research and Development Expense of $109.00 million for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-11
- Johnson & Johnson research and development expense for fiscal 2025 was $109.00M, a 94.08% decline from fiscal 2024.
- Johnson & Johnson research and development expense for fiscal 2024 was $1.84B, a 281.16% increase from fiscal 2023.
- Johnson & Johnson research and development expense for fiscal 2023 was $483.00M.
- Johnson & Johnson research and development expense for fiscal 2023 was $0.00.
| Period end | Research and Development Expense 12 month |
|---|---|
| 2025-12-28 | $109.00M 10-K · filed 2026-02-11 |
| 2024-12-29 | $1.84B 10-K · filed 2026-02-11 |
| 2023-12-31 | $483.00M 10-K · filed 2026-02-11 |
| 2023-01-01 | $0.00 10-K · filed 2025-02-13 |
| 2022-01-02 | $0.00 10-K · filed 2024-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |